Doctors inclined to prescribe new Alzheimer’s drug despite concerns

Jared Whitlock

Features Editor

Beth Snyder Bulik

Senior Editor

Doctors who treat Alzheimer’s patients say they’re likely to prescribe Eisai and Biogen’s new therapy approved Friday, but sounded notes of caution over the lack …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Doctors inclined to prescribe new Alzheimer’s drug despite concerns

Jared Whitlock

Features Editor

Beth Snyder Bulik

Senior Editor

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

FDA picks controversial doctor Vinay Prasad as CBER director, in about-face from Marks

Brian Armstrong’s NewLimit raises a $130M Series B, laying out road map for anti-aging drugs

Vertex pauses study of mRNA therapy for cystic fibrosis

Lilly to pay up to $415M in ALS deal; Actuate’s mid-stage pancreatic cancer data

Bristol Myers to lay off over 500 workers in New Jersey

In one of the riskiest industries — Biotech — a surefire way to neutralize some of that risk emerges

Doc­tors in­clined to pre­scribe new Alzheimer’s drug de­spite con­cerns

Features Editor

Senior Editor

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Doctors inclined to prescribe new Alzheimer’s drug despite concerns